benserazide has been researched along with Abnormal Movements in 10 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations." | 9.14 | Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. ( Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010) |
| "The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations." | 5.14 | Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. ( Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010) |
| "Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded." | 2.75 | Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. ( Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O, 2010) |
| "Other efficacy variables (Unified Parkinson's Disease Rating Scale II, III, and IVb and Investigator's Global Assessment scores) improved significantly after switching to tolcapone." | 2.75 | Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. ( Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R, 2010) |
| "Maximal dyskinesias scores of the MPTP monkeys correlated significantly with [(3)H]Ro25-6981 specific binding in the rostral and caudal striatum." | 1.35 | Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. ( Belkhir, S; Di Paolo, T; Dridi, M; Grégoire, L; Meltzer, LT; Morissette, M; Ouattara, B; Samadi, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Porras, G | 1 |
| De Deurwaerdere, P | 1 |
| Li, Q | 1 |
| Marti, M | 1 |
| Morgenstern, R | 1 |
| Sohr, R | 1 |
| Bezard, E | 1 |
| Morari, M | 1 |
| Meissner, WG | 1 |
| Hattori, N | 1 |
| Xie, CL | 1 |
| Wang, WW | 1 |
| Zhang, SF | 1 |
| Yuan, ML | 1 |
| Che, JY | 1 |
| Gan, J | 1 |
| Song, L | 1 |
| Yuan, WE | 1 |
| Liu, ZG | 1 |
| Ouattara, B | 1 |
| Belkhir, S | 1 |
| Morissette, M | 1 |
| Dridi, M | 1 |
| Samadi, P | 1 |
| Grégoire, L | 1 |
| Meltzer, LT | 1 |
| Di Paolo, T | 1 |
| Yuan, CX | 1 |
| Ye, Q | 1 |
| Wang, J | 1 |
| Zhang, Y | 1 |
| Yuan, CG | 1 |
| Eggert, K | 2 |
| Skogar, O | 1 |
| Amar, K | 1 |
| Luotonen, L | 1 |
| Kuoppamäki, M | 1 |
| Leinonen, M | 1 |
| Nissinen, H | 1 |
| Oertel, W | 1 |
| Adamiak, U | 1 |
| Kaldonska, M | 1 |
| Klodowska-Duda, G | 1 |
| Wyska, E | 1 |
| Safranow, K | 1 |
| Bialecka, M | 1 |
| Gawronska-Szklarz, B | 1 |
| Ries, V | 1 |
| Selzer, R | 1 |
| Eichhorn, T | 1 |
| Oertel, WH | 1 |
| Ohlin, KE | 1 |
| Sebastianutto, I | 1 |
| Adkins, CE | 1 |
| Lundblad, C | 1 |
| Lockman, PR | 1 |
| Cenci, MA | 1 |
| Martinelli, P | 1 |
| Contin, M | 1 |
| Scaglione, C | 1 |
| Riva, R | 1 |
| Albani, F | 1 |
| Baruzzi, A | 1 |
1 review available for benserazide and Abnormal Movements
| Article | Year |
|---|---|
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].
Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinat | 2014 |
3 trials available for benserazide and Abnormal Movements
| Article | Year |
|---|---|
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse | 2010 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzoph | 2010 |
6 other studies available for benserazide and Abnormal Movements
| Article | Year |
|---|---|
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, | 2014 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Pr | 2014 |
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Autoradiography; Behavior, Animal; Benserazide; Benzoxazoles; Cabergoline; Corpus Striatum; | 2009 |
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias].
Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopami | 2008 |
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Bensera | 2012 |
Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benserazide; Case-Control Studies; Dyskinesias; Female | 2003 |